 |
Keratinocyte Transfection Reagent |
|
|
Catalog # 1783 - 0.5 mL $ 126.00
Catalog # 1784 - 1.5 mL $ 269.00
Transfection reagent for Keratinocyte cells
- Kit includes Transfection Enhancer reagent and recommended transfection protocols
- Protocols provided for transfection of microRNA and siRNA
- High transfection efficiency
- Optimized for Keratinocyte cells
- Compatible with transfection in any plate format
- Reproducible transfection
- Ideal for primary cells
- Developed and manufactured by Altogen Biosystems
Transfection Efficiency:
Reagent exhibits at least 85% transfection efficiency of siRNA delivery. Transfection efficiency was determined by real-time RT-PCR.
Transfection Protocol:
Transfection protocols are provided with the purchase of the reagent.
|
 |
DATA |
|
Figure 1. Cyclophilin B silencing efficiency was determined by qRT-PCR in the cells transfected by Cyclophilin B siRNA or non-silencing siRNA control following the recommended transfection protocol. Cyclophilin mRNA expression levels were measured 48 hours post-transfection. 18S rRNA levels were used to normalize the Cyclophilin B data. Values are normalized to untreated sample. Data are presented as means ± SD (n=3).
 |
Keratinocyte Cells |
|
Keratinocyte cells originate in the basal skin layer and grow densely outward through the layers of the epidermis. Keratinocyte cells are continuously shed and replaced from the outer layer They are the most common type of skin cell. They are considered the building blocks of skin because they make keratin. Keratinocyte cells are tightly interwoven and form seams between the nerves and underlying tissues of the epidermis. This allows them to create a protective barrier to prevent infectious substances coming into the body through the skin. Keratinocytes are used to develop in vitro techniques to assess skin irritants. The cells are also the principal source of the proinflammatory cytokine IL-1? in the epidermis. Studies have found that Bcl-2 overexpression protects human keratinocyte cells from Ukrain-induced apoptosis but not from G2/M arrest.
 |
Altogen Biosystems |
|
Altogen Biosystems is a life sciences company dedicated to the development, marketing and manufacture of cell type specific transfection reagents. Efficient delivery of DNA, RNA, siRNA, and microRNA enabled by advanced formulation of reagents and peculiar design of protocols. Altogen Biosystems offers a complete transfection system for a broad range of cell lines. All reagents are functionally tested to be highly reproducible, serum compatible, induce low toxicity, and can be used for co-transfection experiments, and high throughput applications.
 |
Transfection Resource |
|
siRNA Transfection || Transfection Methods || Stable Transfection || RNAi || siRNA Library Screening || RNAi Therapeutics || Cell Transfection || In Vivo Transfection Reagents || Cell Line Specific Transfection Reagents
 |
Featured Products |
|
In Vivo Transfection Reagents || Fibroblast Cells Transfection Reagent || Astrocyte Cells Transfection Reagent || HEK-293 Transfection Reagent || MEF Transfection Reagent || HepG2 Transfection Reagent || CHO Reagent || MDA-MB Transfection Reagent || Cos7 Transfection Reagent || A549 Transfection Reagent || NIH3T3 Reagent || HUVEC Transfection Reagent || LNCaP Transfection Reagent || MCF-7 Reagent || PC-12 Reagent
 |
Altogen Research Services |
|
Altogen Custom Services provide specialized biotechnology and pharmaceutical services, including - generation of stable cell lines, RNA Interference (RNAi) services, assay development, screening and transfection services. Generation of stably-expressing cancer cell lines and primary cells can be very expensive and time-consuming. Altogen Services offers generation of stable cell lines by transforming the cell line of choice to stably express gene of interest or shRNA-encoding construct. Cloning and shRNA expression services are available.
|